Lennox-Gastaut syndrome Market to Expand Significantly by 2034, States DelveInsight Report | Takeda, Ovid, SK Life Science, Epygenix, CuroNZ Ltd, Eisai

The Key Lennox–Gastaut syndrome Companies: in the market include - Takeda /Ovid, SK Life Science, Inc., Epygenix, CuroNZ Ltd, Eisai, and others.

 

The Lennox–Gastaut syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Lennox–Gastaut syndrome pipeline products will significantly revolutionize the Lennox–Gastaut syndrome market dynamics.

 

DelveInsight’s “Lennox–Gastaut syndrome Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Lennox–Gastaut syndrome, historical and forecasted epidemiology as well as the Lennox–Gastaut syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Lennox–Gastaut syndrome market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

 

To Know in detail about the Lennox–Gastaut syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Lennox–Gastaut syndrome Market Forecast

 

Some of the key facts of the Lennox–Gastaut syndrome Market Report:

• The Lennox–Gastaut syndrome market size was valued ~596 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In June 2024, UCB, a global biopharmaceutical company, announced that Epilepsia published results from a comprehensive scoping review evaluating the effectiveness of FINTEPLA® (fenfluramine) in reducing the frequency of generalized tonic-clonic seizures (GTCS) and tonic-clonic seizures (TCS) in patients with developmental and epileptic encephalopathies (DEEs). The review demonstrated a significant reduction in both GTCS and TCS across various DEEs, further supporting the data from the FINTEPLA clinical trial program. FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for treating seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients aged two years and older.

• In June 2024, Takeda (TSE:4502/NYSE:TAK) has announced topline results from its SKYLINE and SKYWAY studies. SKYLINE (TAK-935-3001) was a multicenter, randomized, double-blind Phase 3 trial that assessed soticlestat (TAK-935) in combination with standard care versus placebo plus standard care in patients with refractory Dravet syndrome (DS). While soticlestat did not meet the primary endpoint of reducing convulsive seizure frequency compared to placebo (p-value = 0.06), it showed clinically meaningful and nominally significant results in six key secondary endpoints, including responder rates, caregiver and clinician global impressions of improvement, and seizure intensity and duration scales during the 16-week treatment period (all p-values ≤ 0.008).

• DelveInsight's analysis forecasts that the Lennox-Gastaut Syndrome market will expand at a CAGR of 4.5% from 2024 to 2034.

• According to DelveInsight's epidemiology model, there were approximately 115,000 prevalent cases of Lennox-Gastaut Syndrome in the 7MM in 2023. This figure is expected to increase over the forecast period (2024-2034), largely due to heightened awareness and advancements in diagnostic methods.

• In 2023, the diagnosed prevalent cases of Lennox-Gastaut Syndrome across the 7MM totaled approximately 81,000. This number is expected to increase throughout the forecast period.

• In 2023, the United States recorded the highest number of diagnosed prevalent cases of Lennox-Gastaut Syndrome, with around 34,000 cases, a figure projected to rise throughout the forecast period.

• In 2023, the diagnosed prevalent cases of Lennox-Gastaut Syndrome in the US were distributed by gender, with males representing about 25,000 cases and females accounting for approximately 9,000 cases.

• In 2023, among the EU4 and the UK, Germany recorded the highest number of diagnosed prevalent cases of Lennox-Gastaut Syndrome, with roughly 11,000 cases. France followed with approximately 9,600 cases, and Italy had around 8,800 cases.

• In 2023, Japan had the fewest diagnosed prevalent cases of Lennox-Gastaut Syndrome, with around 3,000 cases.

• Key Lennox–Gastaut syndrome Companies: Takeda /Ovid, SK Life Science, Inc., Epygenix, CuroNZ Ltd, Eisai, and others

• Key Lennox–Gastaut syndrome Therapies: Soticlestat, Carisbamate, EPX-100, NRP2945, Fycompa, TAK-935/OV935 (Soticlestat), and others

• The Lennox–Gastaut syndrome epidemiology based on gender analyzed that Lennox–Gastaut syndrome is found to be more prevalent in males than in females, for some undefined reason, with the male to female ratio being 1:6 (relative risk, 5.31).

 

Lennox–Gastaut syndrome Overview

Lennox-Gastaut syndrome (LGS) is a rare and severe form of epilepsy that typically begins in early childhood, often between ages 3 and 5. It is characterized by multiple types of seizures, including tonic (stiffening) and atonic (loss of muscle tone) seizures. People with LGS also experience developmental delays, cognitive impairments, and behavioral issues. The causes of LGS can vary, including genetic factors, brain injury, or other underlying conditions. Treatment usually involves a combination of medications, and in some cases, surgery or dietary therapies, to manage the seizures and improve quality of life.

 

Get a Free sample for the Lennox–Gastaut syndrome Market Report -

https://www.delveinsight.com/report-store/lennox-gastaut-syndrome-market

 

Lennox–Gastaut syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Lennox–Gastaut syndrome Epidemiology Segmentation:

The Lennox–Gastaut syndrome market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalent Cases of Lennox–Gastaut syndrome in the 7MM

• Total Diagnosed Prevalent Cases of Lennox–Gastaut syndrome in the 7MM

• Gender-specific Diagnosed Prevalent Cases of Lennox–Gastaut syndrome in the 7MM

• Seizures-specific Diagnosed Prevalent Cases of Lennox Gastaut syndrome in the 7MM

 

Download the report to understand which factors are driving Lennox–Gastaut syndrome epidemiology trends @ Lennox–Gastaut syndrome Epidemiological Insights

 

Lennox–Gastaut syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Lennox–Gastaut syndrome market or expected to get launched during the study period. The analysis covers Lennox–Gastaut syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Lennox–Gastaut syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Lennox–Gastaut syndrome Therapies and Key Companies

• Soticlestat: Takeda /Ovid

• Carisbamate: SK Life Science, Inc.

• EPX-100: Epygenix

• NRP2945: CuroNZ Ltd

• Fycompa: Eisai

• TAK-935/OV935 (Soticlestat): Takeda /Ovid

 

To know more about Lennox–Gastaut syndrome treatment, visit @ Lennox–Gastaut syndrome Medications

 

Lennox–Gastaut syndrome Market Strengths

• The use of off-label branded and generic prescription medications targeted at individual symptoms of LennoxGastaut syndrome (LGS)

 

Lennox–Gastaut syndrome Market Opportunities

• New therapeutic options are needed to address the unmet need for effective and curative therapies for Lennox-Gastaut syndrome (LGS).

 

Scope of the Lennox–Gastaut syndrome Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Lennox–Gastaut syndrome Companies: Takeda /Ovid, SK Life Science, Inc., Epygenix, CuroNZ Ltd, Eisai, Takeda, Ovid, and others

• Key Lennox–Gastaut syndrome Therapies: Soticlestat, Carisbamate, EPX-100, NRP2945, Fycompa, TAK-935/OV935 (Soticlestat), and others

• Lennox–Gastaut syndrome Therapeutic Assessment: Lennox–Gastaut syndrome current marketed and Lennox–Gastaut syndrome emerging therapies

• Lennox–Gastaut syndrome Market Dynamics: Lennox–Gastaut syndrome market drivers and Lennox–Gastaut syndrome market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Lennox–Gastaut syndrome Unmet Needs, KOL’s views, Analyst’s views, Lennox–Gastaut syndrome Market Access and Reimbursement

 

Discover more about therapies set to grab major Lennox–Gastaut syndrome market share @ Lennox–Gastaut syndrome Treatment Landscape

 

Table of Contents

1. Lennox–Gastaut syndrome Market Report Introduction

2. Executive Summary for Lennox–Gastaut syndrome

3. SWOT analysis of Lennox–Gastaut syndrome

4. Lennox–Gastaut syndrome Patient Share (%) Overview at a Glance

5. Lennox–Gastaut syndrome Market Overview at a Glance

6. Lennox–Gastaut syndrome Disease Background and Overview

7. Lennox–Gastaut syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Lennox–Gastaut syndrome

9. Lennox–Gastaut syndrome Current Treatment and Medical Practices

10. Lennox–Gastaut syndrome Unmet Needs

11. Lennox–Gastaut syndrome Emerging Therapies

12. Lennox–Gastaut syndrome Market Outlook

13. Country-Wise Lennox–Gastaut syndrome Market Analysis (2020–2034)

14. Lennox–Gastaut syndrome Market Access and Reimbursement of Therapies

15. Lennox–Gastaut syndrome Market Drivers

16. Lennox–Gastaut syndrome Market Barriers

17. Lennox–Gastaut syndrome Appendix

18. Lennox–Gastaut syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

EGFR Non Small Cell Lung Cancer Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Bridge Biotherapeutics, Inc., Sichuan Kelun Pharmaceutical

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, EGFR Non Small Cell Lung Cancer pipeline constitutes 25+ key companies continuously working towards developing 30+ EGFR Non Small Cell Lung Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

The EGFR Non Small Cell Lung Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“EGFR Non Small Cell Lung Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the EGFR Non Small Cell Lung Cancer Market.

 

Some of the key takeaways from the EGFR Non Small Cell Lung Cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel EGFR Non Small Cell Lung Cancer treatment therapies with a considerable amount of success over the years.

• EGFR Non Small Cell Lung Cancer companies working in the treatment market are Bridge Biotherapeutics, Inc., Sichuan Kelun Pharmaceutical, BeBetter Med Inc, Avistone Biotechnology, Therapex Co., Ltd, Dizal Pharmaceuticals, Betta Pharmaceuticals, AstraZeneca, Taiho Oncology, Avistone Pharmaceuticals, Black Diamond Therapeutics, Bayer, Bridge Therapeutics, RedCloud Bio, J Ints Bio, Cullinan Oncology, TYK Medicine, and others, are developing therapies for the EGFR Non Small Cell Lung Cancer treatment

• Emerging EGFR Non Small Cell Lung Cancer therapies in the different phases of clinical trials are- BBT-207, SKB264, BEBT-109, Vebreltinib, TRX-221, DZD9008, D-0316 Capsule, Osimertinib, TAS3351 oral administration, PLB1004, BDTX-1535, BAY2927088, BBT-176, H002, JIN-A02, CLN-081, TY-9591, and others are expected to have a significant impact on the EGFR Non Small Cell Lung Cancer market in the coming years.

• In January 2025, BlossomHill Therapeutics, Inc., a privately-held clinical-stage biotechnology company specializing in small molecule therapies for cancer and autoimmune diseases, has announced the dosing of the first patient cohort in the SOLARA study (NCT06706076). SOLARA is a global, open-label, Phase 1/2 dose escalation and expansion trial evaluating the safety, efficacy, and tolerability of BH-30643 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR or HER2 mutations.

• In January 2025, AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US and granted Priority Review. The application seeks approval for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) who have previously undergone systemic therapies, including an EGFR-targeted treatment.

• In July 2024, Delta-Fly Pharma has begun enrolling participants in its Phase III clinical trial of DFP-14323 for treating non-small cell lung cancer (NSCLC). The trial aims to assess the combination of DFP-14323 with a 20mg daily dose of Afatinib, compared to a 40mg daily dose of Afatinib alone. The study will include stage III/IV NSCLC patients in Japan with uncommon EGFR mutations.

• In March 2024, InnoCare Pharma has administered the first dose in a Phase Ib clinical trial evaluating the combination of its drug ICP-189 with ArriVent BioPharma’s furmonertinib for treating non-small cell lung cancer (NSCLC). ICP-189, developed by InnoCare, is an allosteric inhibitor of Src Homology 2 domain containing protein tyrosine phosphatase (SHP2), while furmonertinib is a brain-penetrant, mutation-selective inhibitor of the epidermal growth factor receptor (EGFR). ICP-189 is intended to target solid tumors, either as a monotherapy or in combination with other antitumor agents.

• In September 2023, The Janssen Pharmaceutical Companies of Johnson & Johnson announced positive top-line results from the Phase 3 MARIPOSA study. This study evaluated RYBREVANT® (amivantamab-vmjw), a bispecific antibody targeting the epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET), combined with lazertinib, an oral third-generation EGFR tyrosine kinase inhibitor (TKI), against osimertinib as a first-line treatment for patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC).

• In October 2023, Today, the Janssen Pharmaceutical Companies of Johnson & Johnson announced the findings of the Phase 3 MARIPOSA-2 study, which demonstrated that the combination of chemotherapy and RYBREVANT® (amivantamab-vmjw), given with or without lazertinib, reduced the risk of death or disease progression by 56% and 56%, respectively (Hazard Ratio [HR]=0.44; 95 percent Confidence Interval [CI], 0.35–0.56; p value P

 

EGFR Non Small Cell Lung Cancer Overview

EGFR-positive non-small cell lung cancer (NSCLC) is a subtype of lung cancer characterized by mutations in the epidermal growth factor receptor (EGFR) gene

 

Get a Free Sample PDF Report to know more about EGFR Non Small Cell Lung Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/egfr-non-small-cell-lung-cancer-egfr-nsclc-pipeline-insight

 

Emerging EGFR Non Small Cell Lung Cancer Drugs Under Different Phases of Clinical Development Include:

• BBT-207: Bridge Biotherapeutics, Inc.

• SKB264: Sichuan Kelun Pharmaceutical

• BEBT-109: BeBetter Med Inc

• Vebreltinib: Avistone Biotechnology

• TRX-221: Therapex Co., Ltd

• DZD9008: Dizal Pharmaceuticals

• D-0316 Capsule: Betta Pharmaceuticals

• Osimertinib: AstraZeneca

• TAS3351 oral administration: Taiho Oncology

• PLB1004: Avistone Pharmaceuticals

• BDTX-1535: Black Diamond Therapeutics

• BAY2927088: Bayer

• BBT-176: Bridge Therapeutics

• H002: RedCloud Bio

• JIN-A02: J Ints Bio

• CLN-081: Cullinan Oncology

• TY-9591: TYK Medicine

 

EGFR Non Small Cell Lung Cancer Route of Administration

EGFR Non Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

 

EGFR Non Small Cell Lung Cancer Molecule Type

EGFR Non Small Cell Lung Cancer Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

 

EGFR Non Small Cell Lung Cancer Pipeline Therapeutics Assessment

• EGFR Non Small Cell Lung Cancer Assessment by Product Type

• EGFR Non Small Cell Lung Cancer By Stage and Product Type

• EGFR Non Small Cell Lung Cancer Assessment by Route of Administration

• EGFR Non Small Cell Lung Cancer By Stage and Route of Administration

• EGFR Non Small Cell Lung Cancer Assessment by Molecule Type

• EGFR Non Small Cell Lung Cancer by Stage and Molecule Type

 

DelveInsight's EGFR Non Small Cell Lung Cancer Report covers around 30+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

 

Further EGFR Non Small Cell Lung Cancer product details are provided in the report. Download the EGFR Non Small Cell Lung Cancer pipeline report to learn more about the emerging EGFR Non Small Cell Lung Cancer therapies

 

Some of the key companies in the EGFR Non Small Cell Lung Cancer Therapeutics Market include:

Key companies developing therapies for EGFR Non Small Cell Lung Cancer are - Summit Therapeutics, Arcus Biosciences, GlaxoSmithKline, Pfizer, AstraZeneca, Seagen, MacroGenics, Roche, Qilu Pharmaceutical, Shandong New age Pharmaceutical, Symphogen, and others.

 

EGFR Non Small Cell Lung Cancer Pipeline Analysis:

The EGFR Non Small Cell Lung Cancer pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of EGFR Non Small Cell Lung Cancer with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for EGFR Non Small Cell Lung Cancer Treatment.

• EGFR Non Small Cell Lung Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• EGFR Non Small Cell Lung Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the EGFR Non Small Cell Lung Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about EGFR Non Small Cell Lung Cancer drugs and therapies

 

EGFR Non Small Cell Lung Cancer Pipeline Market Drivers

• Increasing prevalence of non-small cell lung cancer, increasing new drug approvals, increase in frequency of diagnosis of NSCLC are some of the important factors that are fueling the EGFR Non Small Cell Lung Cancer Market.

 

EGFR Non Small Cell Lung Cancer Pipeline Market Barriers

• However, high cost of therapies entering the market, requirement of adequate reimbursement policies for NSCLC drugs and other factors are creating obstacles in the EGFR Non Small Cell Lung Cancer Market growth.

 

Scope of EGFR Non Small Cell Lung Cancer Pipeline Drug Insight

• Coverage: Global

• Key EGFR Non Small Cell Lung Cancer Companies: Bridge Biotherapeutics, Inc., Sichuan Kelun Pharmaceutical, BeBetter Med Inc, Avistone Biotechnology, Therapex Co., Ltd, Dizal Pharmaceuticals, Betta Pharmaceuticals, AstraZeneca, Taiho Oncology, Avistone Pharmaceuticals, Black Diamond Therapeutics, Bayer, Bridge Therapeutics, RedCloud Bio, J Ints Bio, Cullinan Oncology, TYK Medicine, and others

• Key EGFR Non Small Cell Lung Cancer Therapies: BBT-207, SKB264, BEBT-109, Vebreltinib, TRX-221, DZD9008, D-0316 Capsule, Osimertinib, TAS3351 oral administration, PLB1004, BDTX-1535, BAY2927088, BBT-176, H002, JIN-A02, CLN-081, TY-9591, and others

• EGFR Non Small Cell Lung Cancer Therapeutic Assessment: EGFR Non Small Cell Lung Cancer current marketed and EGFR Non Small Cell Lung Cancer emerging therapies

• EGFR Non Small Cell Lung Cancer Market Dynamics: EGFR Non Small Cell Lung Cancer market drivers and EGFR Non Small Cell Lung Cancer market barriers

 

Request for Sample PDF Report for EGFR Non Small Cell Lung Cancer Pipeline Assessment and clinical trials

 

Table of Contents

1. EGFR Non Small Cell Lung Cancer Report Introduction

2. EGFR Non Small Cell Lung Cancer Executive Summary

3. EGFR Non Small Cell Lung Cancer Overview

4. EGFR Non Small Cell Lung Cancer- Analytical Perspective In-depth Commercial Assessment

5. EGFR Non Small Cell Lung Cancer Pipeline Therapeutics

6. EGFR Non Small Cell Lung Cancer Late Stage Products (Phase II/III)

7. EGFR Non Small Cell Lung Cancer Mid Stage Products (Phase II)

8. EGFR Non Small Cell Lung Cancer Early Stage Products (Phase I)

9. EGFR Non Small Cell Lung Cancer Preclinical Stage Products

10. EGFR Non Small Cell Lung Cancer Therapeutics Assessment

11. EGFR Non Small Cell Lung Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. EGFR Non Small Cell Lung Cancer Key Companies

14. EGFR Non Small Cell Lung Cancer Key Products

15. EGFR Non Small Cell Lung Cancer Unmet Needs

16 . EGFR Non Small Cell Lung Cancer Market Drivers and Barriers

17. EGFR Non Small Cell Lung Cancer Future Perspectives and Conclusion

18. EGFR Non Small Cell Lung Cancer Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Tendonitis Market Growth Projections 2024-2034: DelveInsight Analysis | TRB Chemedica, CollPlant, Novartis, Orthocell, MiMedX group, InGeneron, R3 Stem Cell

The Key Tendonitis Companies in the market include - TRB Chemedica, CollPlant, Novartis, Orthocell, MiMedX group, InGeneron, Novartis, R3 Stem Cell, Orthocell, and others.

 

The Tendonitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Tendonitis pipeline products will significantly revolutionize the Tendonitis market dynamics.

 

DelveInsight’s “Tendonitis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Tendonitis, historical and forecasted epidemiology as well as the Tendonitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Tendonitis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

 

To Know in detail about the Tendonitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Tendonitis Market Insights

 

Some of the key facts of the Tendonitis Market Report:

• The Tendonitis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In the 7MM, the United States held the largest market share for tendonitis, valued at approximately USD 2,500 million in 2023.

• In the 7MM, the United States recorded the highest number of tendonitis incident cases, exceeding 4 million in 2023.

• Key Tendonitis Companies: TRB Chemedica, CollPlant, Novartis, Orthocell, MiMedX group, InGeneron, Novartis, R3 Stem Cell, Orthocell, and others

• Key Tendonitis Therapies: OSTENIL TENDON, VergenixSTR, Cosentyx (Secukinumab/AIN457), Tendon Cell Therapy, AmnioFix, Adipose-derived regenerative cells (ADRC), Secukinumab, Amniotic stem cells, Ortho-ATI, and others

 

Get a Free sample for the Tendonitis Market Report:

https://www.delveinsight.com/report-store/tendonitis-market

 

Tendonitis Overview

Tendonitis is an inflammation of a tendon – a thick, flexible cord of tissue that attaches muscles to bone and assists in moving the bone or structure. Tendonitis most commonly occurs in the shoulder, bicep, elbow, hand, wrist, thumb, calf, knee, or ankle. Since the pain of tendonitis occurs near a joint, it is sometimes mistaken for arthritis. The condition is more common in adults over the age of 40 and athletes. Some forms of tendonitis are named after certain sports (e.g., tennis elbow, golfer’s elbow, pitcher’s shoulder, swimmer’s shoulder, and jumper’s knee).

 

 

Tendonitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Tendonitis Epidemiology Segmentation:

The Tendonitis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Tendonitis

• Prevalent Cases of Tendonitis by severity

• Gender-specific Prevalence of Tendonitis

• Diagnosed Cases of Episodic and Chronic Tendonitis

 

Download the report to understand which factors are driving Tendonitis epidemiology trends @ Tendonitis Epidemiological Insights

 

Tendonitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Tendonitis market or expected to get launched during the study period. The analysis covers Tendonitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Tendonitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Tendonitis Therapies and Key Companies

• OSTENIL TENDON: TRB Chemedica

• VergenixSTR: CollPlant

• Cosentyx (Secukinumab/AIN457): Novartis

• Tendon Cell Therapy: Orthocell

• AmnioFix: MiMedX group

• Adipose-derived regenerative cells (ADRC): InGeneron

• Secukinumab: Novartis

• Amniotic stem cells: R3 Stem Cell

• Ortho-ATI: Orthocell

 

Discover more about therapies set to grab major Tendonitis market share @ Tendonitis Medications

 

Tendonitis Market Drivers

• Increase in the targeted patient pool

• Novel Tendonitis treatment approaches

 

Tendonitis Market Barriers

• Delayed diagnosis of the disease

• Limitations associated with the current treatment

 

Scope of the Tendonitis Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Tendonitis Companies: TRB Chemedica, CollPlant, Novartis, Orthocell, MiMedX group, InGeneron, Novartis, R3 Stem Cell, Orthocell, and others

• Key Tendonitis Therapies: OSTENIL TENDON, VergenixSTR, Cosentyx (Secukinumab/AIN457), Tendon Cell Therapy, AmnioFix, Adipose-derived regenerative cells (ADRC), Secukinumab, Amniotic stem cells, Ortho-ATI, and others

• Tendonitis Therapeutic Assessment: Tendonitis current marketed and Tendonitis emerging therapies

• Tendonitis Market Dynamics: Tendonitis market drivers and Tendonitis market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Tendonitis Unmet Needs, KOL’s views, Analyst’s views, Tendonitis Market Access and Reimbursement

 

To know more about Tendonitis treatment, visit @ Tendonitis Treatment Landscape

 

Table of Contents

1. Tendonitis Market Report Introduction

2. Executive Summary for Tendonitis

3. SWOT analysis of Tendonitis

4. Tendonitis Patient Share (%) Overview at a Glance

5. Tendonitis Market Overview at a Glance

6. Tendonitis Disease Background and Overview

7. Tendonitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Tendonitis

9. Tendonitis Current Treatment and Medical Practices

10. Tendonitis Unmet Needs

11. Tendonitis Emerging Therapies

12. Tendonitis Market Outlook

13. Country-Wise Tendonitis Market Analysis (2020–2034)

14. Tendonitis Market Access and Reimbursement of Therapies

15. Tendonitis Market Drivers

16. Tendonitis Market Barriers

17. Tendonitis Appendix

18. Tendonitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Vasomotor Symptoms Market on Track for Major Expansion by 2034, According to DelveInsight | Mithra Pharmaceuticals, Bayer, Nerre Therapeutics, Astellas Pharma, MenoGeniX, Estetra, Mitsubishi Tanabe

The Key Vasomotor Symptoms Companies in the market include - Mithra Pharmaceuticals, Bayer/Nerre Therapeutics, Astellas Pharma, MenoGeniX, Estetra, Mitsubishi Tanabe Pharma, QUE Oncology, Bayer, Duramed Research, Mitsubishi Tanabe Pharma, Pfizer, Fervent Pharma, Astellas Pharma, Merck Sharp & Dohme, Que Oncology, Eli Lilly and Company, and others.

 

DelveInsight’s “Vasomotor Symptoms Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Vasomotor Symptoms, historical and forecasted epidemiology as well as the Vasomotor Symptoms market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Vasomotor Symptoms market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Vasomotor Symptoms Market Forecast

 

Some of the key facts of the Vasomotor Symptoms Market Report:

• The Vasomotor Symptoms market size was vlaued ~USD 2,100 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In January 2025, Bayer reported positive topline results from the Phase III OASIS 4 trial evaluating elinzanetant as a non-hormonal treatment for moderate to severe vasomotor symptoms (VMS) in women undergoing adjuvant endocrine therapy for breast cancer or at high risk of the disease. The study met its primary endpoints, showing statistically significant reductions in the frequency of moderate to severe VMS from baseline to weeks 4 and 12 compared to placebo. Additionally, all secondary endpoints were achieved, including reductions in VMS severity at weeks 4 and 12, early symptom relief by week 1, and sustained efficacy throughout the study duration.

• In August 2024, Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura) has announced the dosing of the first patient in the HIGHLIGHT 1™ Phase 3 pivotal study for fezolinetant, an investigational oral, non-hormonal compound being evaluated for the treatment of moderate to severe vasomotor symptoms (VMS) in women with breast cancer undergoing adjuvant endocrine therapy.

• In May 2024, Noema Pharma AG, a clinical-stage biotech firm focused on debilitating neuroscience-related disorders, has announced that the first patient has been dosed in a Phase 2a open-label study assessing the safety and efficacy of NOE-115, a broad-spectrum monoamine modulator, in women experiencing vasomotor symptoms (VMS, commonly known as “hot flashes”) along with other menopause-related issues such as weight gain, daytime fatigue, and cognitive challenges.

• In 2023, the total prevalent cases of Vasomotor Symptoms were approximately 136 million across the 7MM, with a slight decrease anticipated by 2034 at a mild CAGR. The US reported the highest number of prevalent cases of Vasomotor Symptoms within the 7MM.

• In 2023, the prevalent cases of Vasomotor Symptoms in the EU4 and the UK were approximately 59.5 million, with an estimated decline expected by 2034 at a mild CAGR. Germany recorded the highest number of prevalent cases of Vasomotor Symptoms among the EU4 and the UK.

• According to DelveInsight's estimates, in 2023, the highest proportion of prevalent cases of Vasomotor Symptoms in the 7MM was found in the 60–65 age group (approximately 27%), followed by the 55–59 and 50–54 age groups. The fewest cases were recorded in the 40–44 age group.

• According to our analysis, in 2023, there were approximately 41 million cases of hot flashes and about 38 million cases of night sweats in the 7MM. Of the total cases of hot flashes, around 64% were classified as mild, 22% as moderate, and 14% as severe within the 7MM.

• As per DelveInsight's estimates, there were approximately 7.5 million treated cases of Vasomotor Symptoms in the 7MM in 2023.

• Key Vasomotor Symptoms Companies: Mithra Pharmaceuticals, Bayer/Nerre Therapeutics, Astellas Pharma, MenoGeniX, Estetra, Mitsubishi Tanabe Pharma, QUE Oncology, Bayer, Duramed Research, Mitsubishi Tanabe Pharma, Pfizer, Fervent Pharma, Astellas Pharma, Merck Sharp & Dohme, Que Oncology, Eli Lilly and Company, and others

• Key Vasomotor Symptoms Therapies: Donesta(E4, Estetrol), Elinzanetant (BAY-3427080, NT 814), Fezolinetant (ESN-364), MNGX-100 (Filgrastim, G-CSF), Elismetrep(MT-8554), Q-122 (MSX-122), Estetrol, Angeliq (Drospirenone/17ß-estradiol, BAY86-4891), SCE-B, MT-8554, desvenlafaxine succinate, DVS-233 SR, FP-101, Estradiol/DRSP, fezolinetant, esmirtazapine, Q-122, Raloxifene, and others

• The Vasomotor Symptoms epidemiology based on age-specific cases analyzed that Vasomotor Symptoms is most prevalent in females at an age of 60–65 years old

• The Vasomotor Symptoms market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Vasomotor Symptoms pipeline products will significantly revolutionize the Vasomotor Symptoms market dynamics.

 

Vasomotor Symptoms Overview

Vasomotor symptoms (VMS) refer to a group of symptoms related to changes in blood vessel function, particularly in the context of hormonal fluctuations. These symptoms commonly occur during menopause but can also be experienced during other life stages or as a result of certain medical conditions or treatments.

 

Get a Free sample for the Vasomotor Symptoms Market Report:

https://www.delveinsight.com/report-store/vasomotor-symptoms-market

 

Vasomotor Symptoms Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Vasomotor Symptoms Epidemiology Segmentation:

The Vasomotor Symptoms market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalent Cases of Vasomotor Symptoms in the 7MM

• Total Age-specific Cases of Vasomotor Symptoms in the 7MM

• Total Severity-specific Cases of Vasomotor Symptoms in the 7MM

• Total Treated Cases of Vasomotor Symptoms in the 7MM

 

Download the report to understand which factors are driving Vasomotor Symptoms epidemiology trends @ Vasomotor Symptoms Epidemiology Forecast

 

Vasomotor Symptoms Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Vasomotor Symptoms market or expected to get launched during the study period. The analysis covers Vasomotor Symptoms market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Vasomotor Symptoms Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Vasomotor Symptoms Therapies and Key Companies

• Donesta(E4, Estetrol): Mithra Pharmaceuticals

• Elinzanetant (BAY-3427080, NT 814): Bayer/Nerre Therapeutics

• Fezolinetant (ESN-364): Astellas Pharma

• MNGX-100 (Filgrastim, G-CSF): MenoGeniX

• Elismetrep(MT-8554): Mitsubishi Tanabe Pharma

• Q-122 (MSX-122): QUE Oncology

• Estetrol: Estetra

• Angeliq (Drospirenone/17ß-estradiol, BAY86-4891): Bayer

• SCE-B: Duramed Research

• MT-8554: Mitsubishi Tanabe Pharma

• desvenlafaxine succinate: Pfizer

• DVS-233 SR: Pfizer

• FP-101: Fervent Pharma

• Estradiol/DRSP: Bayer

• fezolinetant: Astellas Pharma

• esmirtazapine: Merck Sharp & Dohme

• Q-122: Que Oncology

• Raloxifene: Eli Lilly and Company

 

Discover more about therapies set to grab major Vasomotor Symptoms market share @ Vasomotor Symptoms Treatment Market

 

Vasomotor Symptoms Market Strengths

• An increasing population of geriatric women and raising awareness about women's hygiene, dietary habits, and stress indicators have shed light on hormonal imbalances among women.

 

Vasomotor Symptoms Market Opportunities

• Favorable policies initiated by the government to improve women’s health and raise awareness are likely to propel the market and drive various Pharmaceutical companies to conduct R&D activities.

 

Scope of the Vasomotor Symptoms Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Vasomotor Symptoms Companies: Mithra Pharmaceuticals, Bayer/Nerre Therapeutics, Astellas Pharma, MenoGeniX, Estetra, Mitsubishi Tanabe Pharma, QUE Oncology, Bayer, Duramed Research, Mitsubishi Tanabe Pharma, Pfizer, Fervent Pharma, Astellas Pharma, Merck Sharp & Dohme, Que Oncology, Eli Lilly and Company, and others

• Key Vasomotor Symptoms Therapies: Donesta(E4, Estetrol), Elinzanetant (BAY-3427080, NT 814), Fezolinetant (ESN-364), MNGX-100 (Filgrastim, G-CSF), Elismetrep(MT-8554), Q-122 (MSX-122), Estetrol, Angeliq (Drospirenone/17ß-estradiol, BAY86-4891), SCE-B, MT-8554, desvenlafaxine succinate, DVS-233 SR, FP-101, Estradiol/DRSP, fezolinetant, esmirtazapine, Q-122, Raloxifene, and others

• Vasomotor Symptoms Therapeutic Assessment: Vasomotor Symptoms current marketed and Vasomotor Symptoms emerging therapies

• Vasomotor Symptoms Market Dynamics: Vasomotor Symptoms market drivers and Vasomotor Symptoms market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Vasomotor Symptoms Unmet Needs, KOL’s views, Analyst’s views, Vasomotor Symptoms Market Access and Reimbursement

 

To know more about Vasomotor Symptoms companies working in the treatment market, visit @ Vasomotor Symptoms Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Vasomotor Symptoms Market Report Introduction

2. Executive Summary for Vasomotor Symptoms

3. SWOT analysis of Vasomotor Symptoms

4. Vasomotor Symptoms Patient Share (%) Overview at a Glance

5. Vasomotor Symptoms Market Overview at a Glance

6. Vasomotor Symptoms Disease Background and Overview

7. Vasomotor Symptoms Epidemiology and Patient Population

8. Country-Specific Patient Population of Vasomotor Symptoms

9. Vasomotor Symptoms Current Treatment and Medical Practices

10. Vasomotor Symptoms Unmet Needs

11. Vasomotor Symptoms Emerging Therapies

12. Vasomotor Symptoms Market Outlook

13. Country-Wise Vasomotor Symptoms Market Analysis (2020–2034)

14. Vasomotor Symptoms Market Access and Reimbursement of Therapies

15. Vasomotor Symptoms Market Drivers

16. Vasomotor Symptoms Market Barriers

17. Vasomotor Symptoms Appendix

18. Vasomotor Symptoms Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

AV Access Unveils the eShare W90 4K Wireless Conferencing System for Seamless Hybrid Meetings

Hybrid meetings are more popular than ever. The eShare W90 offers a full-featured USB-C input, dual HDMI output, true plug-and-play design, and exceptional affordability, making it an ideal Barco ClickShare alternative for professionals worldwide.

AV Access eShare W90 wireless presentation and conferencing system, when paired with the eShare D30 USB-C casting dongle, enables effortless one-click wireless conferencing. Featuring a full-featured USB-C input, dual HDMI output, quad-view mode, and other advanced capabilities, it significantly boosts hybrid meeting efficiency in small to medium-sized conference rooms.

AV Access, a leading provider of Pro AV and AV over IP solutions, has introduced the eShare W90 wireless conferencing system to its hybrid conferencing lineup. Combined with the new eShare D30 USB-C casting dongle, BizEye80 4K webcam, and AnyCo A6 daisy-chain speakerphone, the eShare W90 serves as a powerful alternative to Barco ClickShare, delivering an ideal solution for seamless hybrid meetings.

Full-Featured USB-C Input & Dual HDMI Outputs

Building on the success of the eShare W80, the eShare W90 boasts a full-featured USB-C port, allowing users to stream video and audio, transfer data at speeds up to 5Gbps, charge their laptop (65W PD), and access the network—all via a single cable.

Additionally, dual HDMI outputs enable connection to two monitors, ensuring crystal-clear visibility. "A key improvement we made is the quad-view mode, which lets users display up to four sources on a single screen—perfect for comparing multiple proposals," said Bill, CTO at AV Access.

Wireless Conferencing with a Single Click

The eShare W90 revolutionizes hybrid meetings by allowing wireless control of USB 3.0 conferencing devices (e.g., webcams, speakerphones, and video bars) when used with the eShare D30 USB-C dongle. Simply plug in the dongle, press the button, and instantly launch a video conference—eliminating cable clutter and the need for complex setup or training.

The system also enables easy content sharing to two large screens via HDMI, USB-C, or wireless casting, supporting AirPlay, Miracast, Chromecast, and dongle-based casting for effortless collaboration across laptops, smartphones, and tablets.

Furthermore, its dual high-speed Ethernet ports allow users to separate internal and guest networks, ensuring secure company data while offering convenient connectivity for visitors.

Exclusive Pre-Sale Offer

"With its full-featured USB-C input, dual HDMI output, wireless conferencing capability, quad-view mode, and unbeatable pricing, the eShare W90 is a cost-effective alternative to Barco ClickShare. It is available now for an initial pre-sale price of only $899.25 on the AV Access official website, with an exclusive 25% discount. The pre-sale runs from April 1 to April 30—don’t miss the chance to upgrade your hybrid meeting system," added Bill.

About AV Access

AV Access is the world's professional manufacturer of advanced Pro AV and AV over IP products, which include HDMI/KVM extenders, splitters, switchers, KVM switches, AV over IP solutions, wireless conference room solutions, etc. Since its establishment, it has been dedicated to offering the ultimate audiovisual experience to the masses with quality-assured and well-designed AV products at honest pricing. AV Access will continue to develop more innovative products and solutions in the fields of smart home, corporate, education, retail, entertainment, health care, etc. Strong R&D, powerful supply chain and excellent management team make AV Access qualified as your faithful partner!

Learn more by visiting www.avaccess.com

Media Contact
Company Name: Actions Global (US) Inc
Contact Person: Shane Jiang
Email:Send Email
Phone: +1-866-629-3923
Address:100 N HOWARD ST STE R
City: City of Spokane
State: Washington 99201
Country: United States
Website: https://www.avaccess.com/

Prurigo Nodularis Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therapeutics

The Key Prurigo Nodularis Companies in the market include - Trevi Therapeutics, Galderma, Genentech, Incyte Corporation, Vyne Therapeutics Inc., Celgene Corporation, Novartis, Pfizer, Regeneron Pharma, and others.

 

DelveInsight’s “Prurigo Nodularis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Prurigo Nodularis, historical and forecasted epidemiology as well as the Prurigo Nodularis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Prurigo Nodularis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Prurigo Nodularis Market Forecast

 

Some of the key facts of the Prurigo Nodularis Market Report:

• The Prurigo Nodularis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In March 2025, Incyte (Nasdaq: INCY) announced findings from its pivotal Phase 3 TRuE-PN clinical trial program, including the TRuE-PN1 and TRuE-PN2 studies, assessing the safety and efficacy of twice-daily ruxolitinib cream 1.5% (Opzelura®), a topical JAK1/2 inhibitor, in adult patients (18 years and older) with prurigo nodularis (PN).

• In March 2025, Incyte (Nasdaq: INCY) announced positive topline results from its pivotal Phase 3 STOP-HS trial assessing the safety and efficacy of povorcitinib (INCB054707), an oral JAK1 inhibitor, in adults (≥18 years) with moderate to severe hidradenitis suppurativa (HS). Povorcitinib, a selective JAK1 inhibitor, is also being investigated in Phase 3 trials for vitiligo and prurigo nodularis (PN) and in Phase 2 trials for asthma and chronic spontaneous urticaria (CSU).

• In February 2025, Galderma (SWX:GALD) announced that the European Commission has granted approval for Nemluvio in the EU to treat both moderate-to-severe atopic dermatitis and prurigo nodularis. Nemluvio is now authorized for subcutaneous use in patients aged 12 and older with moderate-to-severe atopic dermatitis requiring systemic therapy, as well as in adults with moderate-to-severe prurigo nodularis eligible for systemic treatment.

• According to Morgan et al. (2022), the estimated prevalence of prurigo nodularis was recorded at 3.27 cases per 10,000 patients.

• In 2023, among the 7MM, the United States had the largest diagnosed prevalent population of prurigo nodularis.

• As per estimates, in Europe, the highest prevalence of age-specific cases of prurigo nodularis was observed in the 40-59 years age group, representing over 30% of the total cases in 2023.

• DUPIXENT (dupilumab) stands as the sole therapeutic approved by the US FDA for the treatment of prurigo nodularis, with several other treatments currently undergoing development.

• Key Prurigo Nodularis Companies: Trevi Therapeutics, Galderma, Genentech, Incyte Corporation, Vyne Therapeutics Inc., Celgene Corporation, Novartis, Pfizer, Regeneron Pharma, and others

• Key Prurigo Nodularis Therapies: Nalbuphine ER, Nemolizumab, Vixarelimab(KPL-716), Povorcitinib(INCB-54707), Ruxolitinib Cream, INCB054707, serlopitant, CC-10004, Pimecrolimus, Abrocitinib, Dupilumab SAR231893, and others

• The Prurigo Nodularis epidemiology based on gender analyzed that females are affected more as compared to males, in the case of Prurigo Nodularis

• The Prurigo Nodularis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Prurigo Nodularis pipeline products will significantly revolutionize the Prurigo Nodularis market dynamics.

 

Prurigo Nodularis Overview

Prurigo nodularis is a chronic skin condition characterized by the development of intensely itchy nodules or bumps on the skin. These nodules can vary in size and color and often appear on the arms, legs, or trunk. The itching associated with prurigo nodularis can be severe and persistent, leading to scratching and potentially causing further irritation and skin damage. The exact cause of prurigo nodularis is not fully understood, but it is believed to involve a combination of factors such as underlying skin conditions, nerve dysfunction, and immune system abnormalities.

 

Get a Free sample for the Prurigo Nodularis Market Report

https://www.delveinsight.com/report-store/prurigo-nodularis-market

 

Prurigo Nodularis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Prurigo Nodularis Epidemiology Segmentation:

The Prurigo Nodularis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Prurigo Nodularis

• Prevalent Cases of Prurigo Nodularis by severity

• Gender-specific Prevalence of Prurigo Nodularis

• Diagnosed Cases of Episodic and Chronic Prurigo Nodularis

 

Download the report to understand which factors are driving Prurigo Nodularis epidemiology trends @ Prurigo Nodularis Epidemiology Forecast

 

Prurigo Nodularis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Prurigo Nodularis market or expected to get launched during the study period. The analysis covers Prurigo Nodularis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Prurigo Nodularis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Prurigo Nodularis Therapies and Key Companies

• Nalbuphine ER: Trevi Therapeutics

• Nemolizumab: Galderma

• Vixarelimab(KPL-716): Genentech

• Povorcitinib(INCB-54707): Incyte Corporation

• Ruxolitinib Cream: Incyte Corporation

• INCB054707: Incyte Corporation

• serlopitant: Vyne Therapeutics Inc.

• CC-10004: Celgene Corporation

• Pimecrolimus: Novartis

• Abrocitinib: Pfizer

• Dupilumab SAR231893: Regeneron Pharma

 

Discover more about therapies set to grab major Prurigo Nodularis market share @ Prurigo Nodularis Treatment Market

 

Prurigo Nodularis Market Strengths

• Novel drug formulations are unlocking the new market outlook and the potential to improve the QoL of patients suffering from the serious symptoms associated with chronic neurologically mediated conditions for which there are few, if any, treatment options.

• Vixarelimab’s dual mechanism offers potential pruritus relief and nodule improvement in prurigo nodularis.

 

Prurigo Nodularis Market Opportunities

• Increasing population gives a lucrative opportunity to increase the awareness and innovation of therapeutics to drive the prurigo nodularis market.

• Due to one approved drug in the market, there is a huge opportunity for the companies who are coming with novel emerging therapies.

 

Scope of the Prurigo Nodularis Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Prurigo Nodularis Companies: Trevi Therapeutics, Galderma, Genentech, Incyte Corporation, Vyne Therapeutics Inc., Celgene Corporation, Novartis, Pfizer, Regeneron Pharma, and others

• Key Prurigo Nodularis Therapies: Nalbuphine ER, Nemolizumab, Vixarelimab(KPL-716), Povorcitinib(INCB-54707), Ruxolitinib Cream, INCB054707, serlopitant, CC-10004, Pimecrolimus, Abrocitinib, Dupilumab SAR231893, and others

• Prurigo Nodularis Therapeutic Assessment: Prurigo Nodularis current marketed and Prurigo Nodularis emerging therapies

• Prurigo Nodularis Market Dynamics: Prurigo Nodularis market drivers and Prurigo Nodularis market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Prurigo Nodularis Unmet Needs, KOL’s views, Analyst’s views, Prurigo Nodularis Market Access and Reimbursement

 

To know more about Prurigo Nodularis companies working in the treatment market, visit @ Prurigo Nodularis Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Prurigo Nodularis Market Report Introduction

2. Executive Summary for Prurigo Nodularis

3. SWOT analysis of Prurigo Nodularis

4. Prurigo Nodularis Patient Share (%) Overview at a Glance

5. Prurigo Nodularis Market Overview at a Glance

6. Prurigo Nodularis Disease Background and Overview

7. Prurigo Nodularis Epidemiology and Patient Population

8. Country-Specific Patient Population of Prurigo Nodularis

9. Prurigo Nodularis Current Treatment and Medical Practices

10. Prurigo Nodularis Unmet Needs

11. Prurigo Nodularis Emerging Therapies

12. Prurigo Nodularis Market Outlook

13. Country-Wise Prurigo Nodularis Market Analysis (2020–2034)

14. Prurigo Nodularis Market Access and Reimbursement of Therapies

15. Prurigo Nodularis Market Drivers

16. Prurigo Nodularis Market Barriers

17. Prurigo Nodularis Appendix

18. Prurigo Nodularis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Burkitt Lymphoma Market Expected to Witness Significant Growth by 2032 | DelveInsight

The Key Burkitt lymphoma companies in the market include - Jazz Pharmaceuticals, Xencor, ADC Therapeutics, Cothera Bio, Merck, and Cornerstone Pharmaceuticals, among others.

 

The Burkitt lymphoma market is expected to experience significant growth across the seven major markets (7MM), which include the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. This growth is driven by several factors, including the increasing prevalence of the disease, advancements in diagnostic capabilities, and a strong pipeline of new therapies. Key Burkitt lymphoma companies, such as Jazz Pharmaceuticals, Xencor, ADC Therapeutics, Cothera Bio, Merck, and Cornerstone Pharmaceuticals, among others, are leading innovation and addressing unmet treatment needs.

 

DelveInsight's latest comprehensive research report, "Burkitt Lymphoma Market Insight, Epidemiology And Market Forecast — 2032," presents critical insights into the evolving Burkitt lymphoma market landscape across 7MM. The report highlights significant growth in the Burkitt lymphoma treatment market during the forecast period of 2019-2032, driven by increased awareness, improved diagnostic capabilities, and the emergence of novel therapeutics.

 

Download the report to understand which factors are driving the Burkitt lymphoma therapeutic market @ Burkitt lymphoma Market Trends

 

Burkitt lymphoma is an aggressive form of non-Hodgkin B-cell lymphoma that begins in B-cells. The disease is frequently associated with Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), and chromosomal translocations causing overexpression of the oncogene c-myc. While the exact cause remains unknown, geographical factors influence risk patterns, with malaria exposure being significant in endemic regions like Africa and HIV representing the primary risk factor elsewhere. The World Health Organization classifies Burkitt lymphoma into three distinct types: Endemic (primarily affecting African children), Sporadic (occurring globally), and Immunodeficiency-associated (most common in people with HIV).

 

According to epidemiological data cited in the report, Burkitt lymphoma represents approximately half of all malignant non-Hodgkin lymphomas in children and around 2% in adults across Europe and North America, with males being disproportionately affected compared to females. Further research indicates that in children under 18 years old, the incidence is approximately 3-6 cases per 100K children annually. For sporadic Burkitt lymphoma, the estimated annual incidence is 4 per 1 million children under 16 years of age and around 2.5 per 1 million in adults. The immunodeficiency-associated variant has a notably higher incidence of 22 per 100K in the United States.

 

Discover evolving trends in Burkitt lymphoma patient pool forecasts @ Burkitt lymphoma Epidemiology Analysis

 

The DelveInsight report also discusses the current and future treatment strategies for Burkitt lymphoma. The existing treatment market for Burkitt lymphoma primarily focuses on intravenous chemotherapy regimens, utilizing agents such as cyclophosphamide, cytarabine, doxorubicin, etoposide, methotrexate, and vincristine. RITUXAN (GeneNtech/Biogen) remains the only approved drug used in combination with various chemotherapy protocols, including R-CODOX-M, R-IVAC, and DA-EPOCH-R. In some cases, surgical intervention may be necessary to address intestinal complications. The overall cure rate for sporadic Burkitt lymphoma approaches an impressive 90% in pediatric and young adult populations.

 

The Burkitt lymphoma drugs development market shows promising activity with several emerging therapies in the pipeline. Notable among these is ADCT-402 (ADC Therapeutics), an antibody-drug conjugate targeting CD19 on B-cells. PC-002 (Cothera Biosciences) is another investigational agent that works by inhibiting survivin expression in tumor cells. Other notable candidates are CPX-351 (Jazz Pharmaceuticals) and Plamotamab (Xencor). Key companies advancing the Burkitt lymphoma therapeutics market include ADC Therapeutics, Cothera Bio, Merck, and Cornerstone Pharmaceuticals, among others.

 

A robust pipeline of several therapies, including gene-modified cell therapies and small molecules, is under development. In October 2024, the FDA granted Fast Track designation to Cothera Bioscience's clinical program PC-002 for the treatment of relapsed or refractory Burkitt Lymphoma. The clinical outcomes and prognostic implications of rituximab in pediatric B-cell non-Hodgkin lymphoma, including Burkitt lymphoma, which represented 53.2% of cases in the study, show positive results as of March 2025. These recent developments underscore the progress toward improving outcomes for Burkitt lymphoma.

 

Unlock which emerging Burkitt lymphoma drug is expected to capture the largest market share in 7MM by 2034. Visit the Burkitt lymphoma Market Insights

 

According to DelveInsight's analysis, the Burkitt lymphoma market faces several challenges, including delayed diagnosis and limited approved therapeutic options. However, the Burkitt lymphoma market shows substantial growth, driven by increased disease awareness, enhanced healthcare spending, and the introduction of novel targeted therapies with improved efficacy profiles. The robust pipeline of innovative treatments and growing research focus on addressing unmet needs position the Burkitt lymphoma treatment market for significant expansion across the 7MM.

 

Table of Contents

1.	Report Introduction
2.	Executive Summary of Burkitt Lymphoma
3.	SWOT Analysis of Burkitt Lymphoma
4.	Burkitt Lymphoma: Patient Share (%) Overview at a Glance
5.	Burkitt Lymphoma: Market Overview (%) at a Glance
6.	Disease Background and Overview
7.	Epidemiology and Patient Population
8.	Country-Specific Patient Population of Burkitt Lymphoma
9.	Current Treatment and Medical Practices
10.	Patient Journey
11.	Unmet Needs
12.	Key Endpoint of Clinical Trials
13.	Emerging Therapies
14.	Conjoint Analysis of Burkitt Lymphoma Therapies
15.	Burkitt Lymphoma: Market Size of 7MM
16.	Country-Wise Market Analysis (2019-2032)
17.	Market Access and Reimbursement of Burkitt Lymphoma
18.	Market drivers
19.	Market barriers
20.	Appendix
21.	DelveInsight Capabilities
22.	Disclaimer
23.	About DelveInsight

 

Related Reports

B-cell Lymphoma Pipeline Insight

B-cell Lymphoma Pipeline Insight provides comprehensive insights about the B-cell Lymphoma pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the B-cell Lymphoma companies, including Lisocabtagene maraleucel, Hoffmann-La Roche (ROG), Nektar Therapeutics (NKTR), Miltenyi Biomedicine GmbH, AVM Biotechnology, Lin BioScience, Inc, Incyte Corporation (INCY), ADC Therapeutics S.A., Genor Biopharma, Beijing InnoCare Pharma Tech, CARGO Therapeutics (CRGX), Chia Tai Tianqing Pharmaceutical Group, SystImmune, LIBO PHARMA, Abclon, BeiGene, Cellectis, Iovance Biotherapeutics (IOVA), Guangzhou Excelmab, Y-mAbs Therapeutics (YMAB), TG Therapeutics, Sutro Biopharma, AbbVie (ABBV), Aleta Biotherapeutics, Janssen Research & Development, Lantern Pharma, Beijing Immunochina Medical Science and Technology, Bantam Pharmaceutical, Lin Bioscience, SFA Therapeutics, neoX Biotech, March Biosciences, and HUTCHMED (HCM) among others.

 

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight
Contact Person: Arpit Anand
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/